Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, ACC

Point-of-care Biosensors Will Grow to a $33 Billion Market by 2027 Forecasts IDTechEx Research


BOSTON, September 7, 2017 /PRNewswire/ --

The brand-new IDTechEx Research report, Biosensors for Point-of-Care Testing: Technologies, Applications, Forecasts 2017-2027, predicts that point-of-care (PoC) biosensors will become a $33 billion market by 2027, with molecular diagnostic devices the main driver for this growth. The report gives a complete analysis of the important trends in the field of medical biosensors, and lists the new technologies and devices which are likely to be highly disruptive to the in-vitro diagnostics market.

     (Logo: http://photos.prnewswire.com/prnh/20140310/673848 )

     (Photo: http://mma.prnewswire.com/media/553244/IDTechEx_Point_of_Care_Biosensors.jpg )

Biosensors are used to detect and quantify biological material associated with a disease state or health condition (biomarkers). Biosensors are therefore powerful tools for diagnosis and monitoring. As technological advances allow for such tests to be conducted faster and on smaller devices, these tests are moving out of specialised laboratories and closer to the patient at the point-of-care.

This report is the first to comprehensively look at all commercial applications for point-of-care biosensors. It gives a complete picture of the industry, including the types of biosensors, the key players on the market and the emerging technologies.

In this analysis of the market, 'point-of-care' is defined as being portable and able to gives results in under one hour. Commercial biosensors are split in four categories: Lateral flow assays; Electrochemical test strips; Integrated cartridges; and Molecular Diagnostics.

In addition, the report gives a 10-year market forecast segmented by application, including infectious disease self-monitoring, glucose testing, cancer, cardiometabolic, pregnancy & fertility and genetic testing.

All the forecasts in this report show the revenues from the consumables (disposable devices) thereby giving a realistic view of the market size.

Biosensors for Point-of-Care Testing: Technologies, Applications, Forecasts 2017-2027 will be useful to any company wishing to be in the value chain of biosensors (materials suppliers, reagent suppliers, microfluidics, contract manufacturers, foundries). Find out more at http://www.IDTechEx.com/biosensors.

The two authors of the report, Dr Laura Baers and Dr David Pugh, will be presenting their analysis on PoC biosensors at the upcoming Business and Technologies Insight Forums hosted by IDTechEx in Seoul (19-21 September) and Tokyo (27-29 September). These forums address both the business and technological landscapes - providing clarity and significant market data to allow you to understand the real opportunities.


Contact:
Charlotte Hibbert
Marketing & Research Co-ordinator
[email protected]
UK: +44-(0)1223-810286

SOURCE IDTechEx


These press releases may also interest you

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: